21 September 2026
Latham & Watkins Advises Novo Nordisk in Multi-Target Drug Discovery Partnership With Orbis Medicines Worth Up to US$1.4 Billion
Advising firms
Deal team
2 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Aaron Gardner Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Arun Mohan | Latham & Watkins LLP | Associate | corporate | Not stated |
Stated terms
- Stated value
- USD 1.40bn (US$1.4 billion)
- What the figure measures
- Not stated
- Client
- Novo NordiskJoint venture party
- Counterparties
- Orbis Medicines (Joint venture party)